Kraig Labs to expand its Research Team to support Domestic and International efforts

ANN ARBOR, Mich., – October 2, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced the Company is opening its new research and production headquarters in Michigan.  This facility will unite the Company’s ongoing recombinant spider silk production operations with its accelerating research into the creation of ever more powerful spider silk protein technologies. 

 Over the next 30 days, the Company will be relocating its current production operations, from Indiana into its new larger facility, and will transfer key production staff, to ensure continuity of operations.  This new facility offers better environmental control, roughly three times the production space, significantly reduces overhead costs, and, for the first time in the Company’s history, will allow the Company’s research and production teams to work side by side producing today’s spider silk based products, and creating tomorrow’s possibilities.

The Company created two new lead positions within its research group to support the new facility and growing research efforts.  Individuals with strong laboratory experience working in genetic engineered, and interested in taking a lead role in a fast paced, growing Biotechnology Company, are encouraged to apply, Click Here.

“Launching this new larger factory unifies our production and research teams’ efforts.  Having our teams working hand in hand will make us more agile and open up opportunities to move technologies more quickly from the drawing board to tested and validated designs,” said COO Jon Rice.    “In addition to streamlining developmental timelines and enhancing our ability to tailor fibers, we expect to reduce R&D costs, as we generate new spider silk technologies by fully integrating design, creation, testing, and scale up, under a single roof.  Our plan is to have this facility be the global central hub for spider silk technology and the center of our international operations.”

The Company’s domestic operations complement its ongoing work establishing international production centers.  Company management is currently considering three overseas locations for production.  Management is scheduled for meeting with senior central government officials in Hanoi, Vietnam in early October and is in ongoing discussions with another country silk producing country which has expressed interest in working with the Company to scale its spider silk technology.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.kraiglabs.com/newsletter

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Recent events position Kraig Labs with financial continuity and ability to focus on the Company’s Strategic Priorities

ANN ARBOR, Mich., -September 08, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the Company will not renew the equity line with Calm Seas Capital, which expired in June of 2017. 

The Company has maintained a financial relationship with Calm Seas Capital since before the creation of its first transgenic silkworm in 2010.  After careful consideration of its plan for commercialization and expansion, and after reviewing potential alternatives for financing that expansion, the Company’s management has determined it has outgrown the financial relationship. 

In addition to the recently extended U.S. Army contract, the Company implemented several strategic efficiency measures to reduce the Company’s fixed expenses.

“We value Calm Seas Capital’s contributions to many of our accomplishments, including the creation of new transgenics and recombinant fibers, however, given our projections for growth, this is the ideal time to transition for our business model’s next chapters,” said CEO and Founder, Kim Thompson.  “As the Company has grown, and, in light of our plans for future expansion and the Army’s recent exercise of its contract option with us for spider silk, it is timely for the Company to explore other avenues that are better aligned with our long term goals.  We’ve now grown to the point where we believe we have alternative financing options not previously available.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter    

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,”

“foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., -August 22, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB)

(“Company”), the leading developer of spider silk based fibers, today announced that the Company delivered the first Dragon Silk fibers to a medical equipment firm for performance and application suitability testing.

The Company is dedicating its current Dragon Silk production to fulfilling its recently exercised U.S. Army contract, but in recognition of the abundant sample requests that the Company received and due to this healthcare firm’s extensive expertise in medical technology development and innovation, the Company decided to supply a small amount of fibers, to be tested for strength, elasticity, and other properties. 

“It seems like we learn about amazing new potential spider silk medical breakthroughs on a near weekly basis, so we believe that medical technologies will be a very important space for Kraig’s future,” said CEO and Founder Kim Thompson.  “As the promise of our fibers becomes increasingly evident, the tests will allow engineers and product designers to understand our fibers’ unique properties, work to define specific opportunities, and accelerate future fiber innovation.”

“It’s important to note that much of this research is for a commonplace application and it’s in very early stages, yet we hope that the tests help in guiding us in building the blueprint for future fiber designs,” stated Jon Rice, COO.  “Based upon the initial evaluation of the fibers we are already working to modify the properties of the finished threads for these applications.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,”

“foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., -August 2, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the U.S. Army awarded the optional phase of its contract with the Company valued at more than $900,000.  Under this exercised option, the Company will work to design, produce, and deliver additional recombinant spider silk materials tailored for the protective needs of our Soldiers.  With this additional award the total contract is now valued at more than $1.0 million. 

“When I founded this Company it was with the dream that one day we would work with the US Army to produce ultra-high strength materials in support of our Warfighters,” said Company CEO and founder, Kim K. Thomson.  “The Army’s exercise of its option under our agreement validates that dream.  Our team is honored to be working on this noble project and we intend to provide this very important customer with the very best high strength polymers using our recombinant spider silk technology.”

“We are extremely excited to continue our work with the US Army to deliver revolutionary materials to support the Warfighter,” stated Jon Rice, COO.  “Under this new phase we will be working closely with our sponsor agency to match the performance of our spider silk to their specific use cases and protective applications.  I would like to thank our team for the incredible amount of effort they’ve put in to make the first phase of this project a success and express my gratitude to our sponsor for the trust and confidence they’ve placed in us to deliver the next generation of spider silk solutions.   The potential uses of spider silk are nearly limitless, but one of the greatest honors is being able to apply our technology to serving those who dedicate themselves to serving and protecting all of us.”

This additional work on the contract is scheduled to last roughly 12 months and is the Company’s second US Department of Defense award.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,”

“foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – July 24 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that it has identified and selected the location for its operational headquarters in Vietnam.  Located in the heart of Quang Nam province, this area provides a vast supply of skilled workers, close proximity to mulberry fields, and easy access to international air and sea ports.  This location was selected based on a series of productive and successful meetings between representatives of Kraig Labs, provincial leaders, and local silk experts.  The Company plans for this facility to be used for the first shipment of the Company’s transgenic silkworm technology into Vietnam. 

“Identifying our corporate headquarters was an essential part of our application to import our silkworm into Vietnam,” Said COO Jon Rice.  “With this location finalized we are now preparing the final importation documents for submission in order to obtain approvals to begin work with our hybrid silk technology in Vietnam.”

In addition to progress made in securing a new Vietnamese headquarters the Company has also been working with local experts to prepare a master plan for the 50 hectares dedicated to this project.  The Company expects to review those plans in the coming weeks.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Labs Installing New Silk Processing Equipment to Speed up Delivery Times for Spider Silk

ANN ARBOR, Mich., – April 17, 2017 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that it is expanding domestic recombinant spider silk production capacity with the purchase and installation of a new commercial scale cocoon processing machine.  This new equipment arrived in early April, is being installed now, and is expected to be fully operational before the end of the month. 

This machine replaces a much smaller cocoon processing machine the Company has been using to produce materials under a contract with the US Army.  The increased capacity and efficiency this new equipment offers will free up production staff and lower overall costs. 

Over the next month the Company plans to supply the Army with sample single filament Dragon Silk fibers for independent testing and to have the first batch of finished Dragon Silk thread ready for knitting into Ballistic shootpacks.  The Company anticipates completing the additional silk necessary for producing the woven shootpacks for the US Army in the third quarter.  This newly installed equipment is expected to play an important role in meeting this new timeline. 

“In many cases, up until now, we’ve been working with research scale equipment as we transitioned out of the laboratory,” said COO Jon Rice.  “We had originally hoped to have completed all silk production for the first Army contact by now.  That timeline, in consultation with our customer, has been extended due to challenges that a third party vendor had in scheduling and processing as well as the throughput limitations of our production facility in its first month of operations.  This new equipment can process more cocoons in one hour than we currently process in a month and it is expected to play an important role in meeting the new timeline.  This new commercial scale machine is expected to sustain our domestic production capacity through 2019 and reduce labor costs significantly.”

In addition to its planned expansion of domestic production, the Company, as earlier announced, is working to establish a significant overseas production operation.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

The issuance of the Investment Certificate is a major step toward high tech silk production in Vietnam

ANN ARBOR, Mich., – March 27, 2017 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that it has just been awarded an Investment Certificate for the production of high technology silk in Vietnam’s Quang Nam province.

The Investment Certificate was issued to the Company during the March 26, 2017 Quang Nam Investment Conference, which was attended by Vietnam’s Prime Minister and numerous high level central government officials, including the ministers of all relevant governmental departments, as well as high level officials from Quang Nam province, including the Chairman and key provincial officials. Representing Kraig Labs at the meeting were the Company’s CEO and Founder, Kim Thompson, and COO, Jon Rice.

“It was an honor to receive this award on stage from the Chairman in front of the Prime Minister,” said Thompson. “This is a huge step forward in our plans to expand production on a large scale. We look forward to the opportunity to revitalize silk production, using high technology, in an area of the world with a strong history of quality silks and textiles.”
This Investment Certificate award was the necessary and final step before the Company seeks central government approval for the expansion of Kraig Labs’ business. The Company’s efforts to secure that final approval are well underway.

“I would like to personally thank the Chairman and his staff for working so closely with us to finalize the Investment Certificate,” stated Rice. “While this is a momentous occasion for Kraig Biocraft Laboratories and our shareholders, it is also a turning point in the commercialization of advanced fibers.”

 
The Investment Conference is receiving significant media coverage in Vietnam, including several English language media outlets.

 
To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter.

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com